GenesisCare joins Vision RT in Global Strategic Partnership

Increasing patient access to world-class precision tattoo-free radiation therapy

GenesisCare, one of the largest providers of radiation therapy services in the world, and Vision RT, a leading provider of Surface Guided Radiation Therapy (SGRT) equipment, today announced a new global strategic partnership to increase patient access to world-class precision radiation therapy technology.

Under the new agreement, Vision RT will supply at least 15 AlignRT systems over 2 years to GenesisCare centres in Australia, US, UK, and Europe, adding to the fleet of pre-existing systems which are available across the GenesisCare network.

AlignRT is a unique radiation therapy system which tracks a patient’s positioning throughout therapy to improve the accuracy of set up and treatment. Prior to this new technology, cancer patients received permanent tattoo marks through traditional radiation therapy to ensure treatment was delivered to a precise location. AlignRT uses 3D stereoscopic camera units and surface tracking to detect slight movements, automatically pausing treatment as needed, to safely deliver highly targeted tattoo-free radiation therapy.

In addition to being able to offer tattoo-free radiation therapy, the AlignRT system also facilitates a technique called Deep Inspiration Breath Hold (DIBH) which will prevent long term cardiac complications during treatment for left side breast cancer, thanks to constant monitoring of the breathing position with extremely fine accuracy.

GenesisCare’s Executive Manager, Service of the Future, Aldo Rolfo, said: “GenesisCare is delighted to be partnering with Vision RT to increase patient access to the latest advancements in SGRT.”

“Having worked in radiation therapy for more than 35 years, I have witnessed the profound emotional impact permanent tattoos can have on our patients, serving as a constant reminder of their diagnosis and treatment.”

“Thanks to our new partnership with Vision RT, GenesisCare centres all over the world will now be able to offer tattoo-free radiation therapy and DIBH, easing the imposition and burden of radiation therapy on patients and their families and reducing long term cardiac complications of treatment.”

“At GenesisCare, we use both Varian and Elekta linear accelerators across our sites worldwide, so seamless integration is vital for us. One of Vision RT’s strengths is their proven ability to integrate with all types of treatment delivery and oncology information systems. Our discussions with both linear accelerator vendors and Vision RT make us confident that this excellent integration will continue into the future.”

Dr. Norman Smith, CEO of Vision RT, said: “We are delighted and extremely proud to be strengthening our relationship with GenesisCare, one of the largest providers of radiation oncology services worldwide. We share the same mission: to improve cancer care for patients around the world. SGRT with AlignRT plays a key part in achieving that mission: improving worldwide patient safety and comfort, treatment accuracy and throughput.”

About GenesisCare

GenesisCare is a Sydney and Australian Headquartered private company and is one of the world’s largest cancer treatment providers. Every year GenesisCare clinical teams see more than 400,000 people at more than 440 locations. This includes our 293 locations in the US, 38 locations in Australia, 14 in the UK, and 21 in Spain. Globally, the organization employs more than 5,500 highly trained physicians, healthcare professionals, and support staff across Australia, the UK, Spain, and the US. Our purpose is to design care experiences that get the best possible life outcomes. We believe that care should be focused on the individual, not the condition, and are proud of our world-class patient satisfaction ratings. For more information, visit genesiscare.com

About Vision RT

Vision RT defines the standard of care in Surface Guided Radiation Therapy (SGRT). With 70 granted patents plus +50 pending, Vision RT continues to innovate in the radiation oncology space and is committed to making SGRT the standard of care for all patients, worldwide. There are more than 1,900 systems installed worldwide.

SGRT, pioneered by Vision RT, uses proprietary 3D stereo camera units to monitor a patient’s skin surface in real-time and compare it to the ideal position with sub-millimetric accuracy. This ensures that radiation is delivered only when a patient is correctly positioned, enhancing safety and comfort. AlignRT is non-invasive and completely non-contact, an increasingly important advantage for cancer patients, who often have weakened immune systems.

AlignRT is being used by nine of the ten “Best Hospitals for Cancer” according to the latest analysis by U.S. News and World Report.

Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 18,000 people, with a total revenue of more than $3 billion.